Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“A standout session at GTH was ‘The immunogenicity of therapeutic proteins in hemostasis – an overview’ by Sebastien Lacroix-Desmazes.
The talk clearly highlighted the immunological challenges in haemophilia — from classical FVIII inhibitors to gene therapy and anti-drug antibodies (ADAs) against newer engineered therapies.
One especially interesting point: FVIII-mimetic bispecific antibodies do not seem to share the same immunogenic profile
- Emicizumab։ ADA signal reported
- NXT007։ ADA signal also observed in early studies
- Mim8։ no ADA signal in the study presented
A likely reason is molecular design:
- Emicizumab is a humanized and highly engineered bispecific antibody; such optimization can improve function, but may also introduce non-self sequences or neoepitopes.
- NXT007, as a further optimized derivative, may retain or add immunogenic determinants.
- Mim8, with a more fully human design strategy, may reduce immune recognition
Take-home message:
Shared mechanism does not equal shared immunogenicity. Even when therapies target the same pathway, immune responses can differ because of humanization strategy, sequence design, and epitope architecture.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper
-
Apr 16, 2026, 13:14Veronica Sanchez: Blood Pressure Categories for Individuals Who Are Pregnant
-
Apr 16, 2026, 13:07Abdul Mannan: Acute Anaphylactic Reaction During Blood Transfusion
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support